

# Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC

Roser Pinyol<sup>1</sup>, Daniela Sia<sup>2</sup>, and Josep M. Llovet<sup>1,2,3</sup>



Next-generation sequencing has provided information on actionable targets and biomarkers of response in oncology. In hepatocellular carcinoma (HCC), Wnt/CTNNB1 mutations characterize the immune-excluded class (cold tumors) and

might represent the biomarkers predicting resistance to immune checkpoint inhibitors. Large-scale validation of these data is needed to customize immunotherapy in advanced HCC.

See related article by Harding et al., p. 2116

In this issue of *Clinical Cancer Research*, Harding and colleagues provide the first report of prospective genotyping of advanced hepatocellular carcinoma (HCC) and the potential implications for clinical decision-making (1). Tumor profiling using the MSK-IMPACT custom panel for targeted exome sequencing (468 genes) was used to inform the treating physician about the actionable genomic alterations harbored by each tumor in 127 patients with advanced HCC (1). This first-in-class study provides three main results that warrant attention: (i) Around 25% of advanced tumors harbored actionable mutations, although overall only 6% of patients received matched therapeutic interventions; (ii) oncogenic PI3K–mTOR alterations might predict sorafenib resistance, as described in 81 HCC-treated patients; and (iii) previously reported immune exclusion HCC class, characterized by Wnt/CTNNB1 mutations (2, 3), might predict primary resistance to immune checkpoint inhibitors, as explored in 31 patients receiving these therapies. Despite some limitations pointed out by the authors related to the small sample size and lack of analysis of confounding factors predicting response, the current data provide novel insights in defining biomarker-driven responses in advanced HCC that deserve confirmation in prospective large-scale clinical investigations.

In HCC, around 40% of patients are diagnosed at advanced stage when systemic therapies are indicated (2). The multi-tyrosine kinase inhibitor (TKI) sorafenib was the first molecular targeted therapy that demonstrated survival benefit in advanced HCC cases (4). More recently, additional TKIs (lenvatinib in first-line, and regorafenib, cabozantinib, and ramucirumab in second-line) have demonstrated survival benefits in the setting of phase III trials. In addition, immune checkpoint inhibitors (nivolumab and pembrolizumab, both in second-line) obtained accelerated FDA approval based upon phase II–positive

clinical signals (2). In spite of such advancements, median survival of these patients is still limited to approximately 12–13 months in frontline and approximately 9–11 months in second-line. No biomarkers are available for tailored treatments, except for AFP >400 ng/mL in patients responding to ramucirumab. In this scenario, a deeper understanding of actionable targets in the clinical practice, mechanisms of response/resistance to identify biomarkers of response and synergies among treatments [immunotherapies (IO) and TKIs/mAbs] are required to ultimately improve patients' survival.

Deep-exome sequencing of HCC tumors has been reported in approximately 1,200 cases (2, 5). These studies, mostly conducted in resected tumors, have delineated that the most prevalent oncogenic drivers in HCC (*TERT*, *TP53*, *CTNNB1*, *AXIN1*, *ARID1A*, and *ARID2*) are currently not actionable. As described for other solid tumor malignancies, in HCC there is also a "long tail" of mutations, amplifications, or deletions at a prevalence of <10%, among which some are amenable for targeted therapies. In this sense, approximately 25% of such alterations have been defined as potentially targetable with the current drug armamentarium (5). These include *FGF19* and *VEGFA* amplifications, *MET* amplifications or mutations, mutations in PI3K–mTOR signaling (*PI3KCA*, *PTEN*, and *TSC1/2*), among others. None of these potential biomarkers have reached a stage in clinical investigation to demonstrate survival benefits, although data with FGFR4 inhibitors in tumors overexpressing *FGF19* are promising.

This study demonstrates that a prospective genotyping approach in patients with advanced HCC is able to identify tumors (24%) with potentially actionable alterations. None of them could receive biomarker-based approved drugs for this indication (level of evidence 1–2A) and only 6% of patients received either drugs approved for another indication (level 2B) or agents in active clinical developments with appealing biomarkers predicting responses (level of evidence 3A and B). Specifically, 5 patients were treated in second-line with either everolimus (based upon *TSC1/2* alterations) or mAbs against *VEGFR2* and *MET* (due to *VEGFR* and *MET* amplifications). Thus, this study, which is the first to report a prospective genotyping of patients with HCC aimed to inform decision-making, describes 24% actionable mutations in advanced tumors, but ultimately only 6% of patients received matched therapeutics. Further approaches including large cohorts of patients are required to demonstrate the cost-effectiveness of this strategy.

Biomarkers predicting response to sorafenib are lacking in advanced HCC (2). Companion studies of the SHARP trial using

<sup>1</sup>Translational Research in Hepatic Oncology, Liver Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Catalonia, Spain. <sup>2</sup>Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. <sup>3</sup>Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.

**Corresponding Author:** Josep M. Llovet, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló 153, Barcelona, Catalonia 08039, Spain. Phone: 349-3227-9155; Fax: 349-3451-5272; E-mail: jmllovet@clinic.cat


doi: 10.1158/1078-0432.CCR-18-3778

©2019 American Association for Cancer Research.

blood-based biomarkers showed a nonsignificant trend for sorafenib benefit in patients with high levels of c-Kit and low levels of HGF. Similarly, a recent study identified a gene signature able to predict sorafenib recurrence-free responders in the adjuvant setting after resection/local ablation, a result that warrants further validation (6). Thus, after more than 10 years of research we lack biomarker guidance to identify sorafenib responders. Only clinical predictors of response, such as HCV-infected HCC and those with liver-only disease, have been associated with a greater benefit with this TKI. In this study, Harding and colleagues report retrospectively that tumors harboring PI3K/mTOR mutations (*PI3KCA*, *PTEN*, and *TSC1/2*) are more likely to be primary resistant to sorafenib (survival of 10.4 months vs. 17.9 months in those without mutations). These mutational alterations accounted for approximately 15% of the tested patients, a figure above the 5% to 10% published by The Cancer Genome Atlas (TCGA) series or in a large meta-analysis (2). Nonetheless, these results represent a positive signal that deserves further investigations.

The most appealing data reported by Harding and colleagues refer to the first confirmation of the hypothesis that HCC "cold" tumors, defined by Wnt/*CTNNB1* mutations (3), are those refractory to immune checkpoint inhibitors (refs. 2, 3; Fig. 1). To identify biomarkers of response to IOs, the authors correlated outcome with the mutational profile of 27 patients receiving

mAbs anti-PD-1/PD-L1 (81%), or anti-CTLA-4, and combinations of anti-PD-1/PD-L1 with anti-CTLA-4, anti-KIR or anti-LAG3 (19%; ref. 1). IOs are more likely to be efficacious in "hot" tumors, as defined by the presence of tumor-infiltrating lymphocytes (TIL). In parallel, tumors displaying immune exclusion, the so-called "cold" tumors, are resistant to IOs. In 2017, our group described a new molecular HCC classification based upon immune traits (2, 5). In brief, approximately 30% of HCCs were enriched by TILs and with molecular features resembling melanomas responsive to IOs, and were defined as HCC immune class (Fig. 1; refs. 2, 5). Conversely, we observed that approximately 30% of patients showed exclusion of TILs, enrichment in *CTNNB1* mutations, and known molecular fingerprints of primary resistance (HCC exclusion class, Fig. 1; refs. 2, 3). Therefore, while tumors within the HCC immune subtype may represent patients most likely to respond to immune checkpoint inhibitors, those within the HCC exclusion class might represent those with innate resistance to anti-PD-1/PD-L1 or similar therapies (2). In their article, Harding and colleagues observed that 10 of 27 patients (37%) treated with IOs exhibited Wnt/*CTNNB1* mutations (7 *CTNNB1*, 3 *AXIN1*). Those 10 patients displaying an altered Wnt-β-catenin pathway were refractory to immune checkpoint blockers (all had progressive disease as best response), with a trend to poorer median survival (9.1



**Figure 1.** Molecular classification of HCC based upon immune status. Around 30% of HCCs belong to the "immune class," with high levels of immune cell infiltration, expression of PD-1 and/or programmed cell death 1 ligand 1 (PD- L1), activation of IFN $\gamma$  signaling, and markers of cytolytic activity (such as granzyme B and perforin 1). These HCC tumors are more likely to respond to immune checkpoint inhibitors. On the other hand, the "immune exclusion class" accounting for approximately 30% of HCCs, is characterized by T-cell exclusion from the tumor microenvironment (TME) and *CTNNB1* mutations. Tumors classified within the HCC exclusion class would represent those with innate resistance to anti-PD-1/PD-L1 inhibitors. Noninflamed tumors with wild-type *CTNNB1* and intermediate levels of immune infiltration (the so-called "immune intermediate class") need to be further characterized to be able to anticipate the response that these patients would have when treated with IOs. Figure partly modified from Llovet and colleagues (2). TIL, tumor-infiltrating lymphocyte.

Downloaded from <http://aacrjournals.org/clinccancerres/article-pdf/25/7/2021/2058517/2021.pdf> by guest on 06 November 2024

months vs. 15.2 months in those without mutations). These results are in line with the seminal study in melanoma demonstrating that non-T-cell-inflamed phenotype displayed altered  $\beta$ -catenin signaling (7). These data are the first clinical signal, to our knowledge, to provide a potential biomarker defining primary resistance to checkpoint inhibitors in HCC. Certainly, whether mutations in *CTNNB1* and *AXIN1* are true biomarkers of innate resistance to IO needs to be validated in the setting of thorough phase II or III clinical trials. Confirmation of these preliminary data would be of utmost importance for the prospect of patient selection and trial enrichment in current and future investigations, and certainly for the precise decision-making in the management of advanced HCC cases.

### Disclosure of Potential Conflicts of Interest

D. Sia and J.M. Llovet are inventors of a patent on immune classifiers to detect immune class. J.M. Llovet reports receiving commercial research grants from

Bayer Healthcare Pharmaceuticals, Eisai, Bristol-Myers Squibb, Ipsen, Blueprint, and Incyte and is a consultant/advisory board member for Eli Lilly, Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb, Eisai, Celsion, Exelixis, Merck, Blueprint, Ipsen, Glycotest, Navigant, Leerink Swann LLC, Midatech Ltd., Fortress Biotech Inc., Spring Bank Pharmaceuticals, Nucleix, and Can-Fite Biopharma. No potential conflicts of interest were disclosed by the other author.

### Acknowledgments

R. Pinyol is funded by the EC and EIT Health. D. Sia is supported by the Gilead Sciences Research Scholar Program in Liver Disease. J.M. Llovet is supported by the NCI (P30-CA196521), U.S. Department of Defense (CA150272P3), European Commission (EC)/Horizon 2020 Program (HEPCAR, Ref. 667273-2), EIT Health (CRISH2, Ref. 18053), Accelerator Award (CRUK, AECC, AIRC; HUNTER, Ref. C9380/A26813), Samuel Waxman Cancer Research Foundation, Spanish NIH (SAF2016-76390), and Generalitat de Catalunya/AGAUR (SGR-1358).

Received December 10, 2018; revised December 17, 2018; accepted January 3, 2019; published first January 7, 2019.

### References

- Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. *Clin Cancer Res* 2019;25:2116–26.
- Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. *Nat Rev Clin Oncol* 2018;15:599–616.
- Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. *Gastroenterology* 2017;153:812–26.
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008;359:378–90.
- Schulze K, Imbeaud S, Letouzé E, Alexandrov L, Calderaro J, Rebouissou S, Couchy G, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. *Nature Genetics* 2015;47:505–1.
- Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau G-Y, et al. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. *Gut* 2018 Aug 14 [Epub ahead of print].
- Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic  $\beta$ -catenin signalling prevents anti-tumour immunity. *Nature* 2015;523:231–5.